Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-aventis confirms sleep improvements with Ambien CR

Sanofi-aventis confirms sleep improvements with Ambien CR

4th January 2008

Sanofi-aventis has confirmed that a new study has shown Ambien CR (zolpidem tartrate extended-release) tablets to improve chronic insomnia in patients with co-morbid chronic insomnia and generalised anxiety disorder (GAD).

The tablets were shown to improve sleep onset, sleep maintenance and total sleep time compared to placebo.

Involving over 380 patients, the study evaluated the overall improvement of insomnia as measured by total sleep time in patients treated with Ambien CR and the antidepressant escitalopram (Lexapro) compared to treatment with placebo and Lexapro.

Thomas Roth, director of sleep disorders at the Henry Ford Hospital, indicated that anxiety experienced by patients with GAD can often lead to sleep problems.

“Data from this study show that Ambien CR can be considered a treatment option for the insomnia in GAD to help them get the full night’s sleep they need to maintain their next-day functioning.”

Patients taking Ambien CR saw their total sleep time increase with week eight results showing an average of 106 minutes more sleep than the baseline.

In addition, Ambien CR-treated patients reported falling asleep sooner and demonstrated improved sleep maintenance, Sanofi-aventis report.

Last month, Sanofi-aventis announced the results of the Trek dose-ranging study of AVE5026, with the compound demonstrating a significant dose response in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.